Organovo Holdings Inc - ONVO Quarterly EPS earnings growth

Organovo Corp - graphic logo of issuer ONVO

Organovo Holdings, Inc. (ONVO) maintains its leadership in 3D bioprinting, protecting its technologies with automation patents. Development relies on the creation of therapeutic liver tissues and collaborations with pharmaceutical companies. Demand is rising due to the shortage of functional organs. The growth rates of quarterly net income per share reflect the business dynamics, where the 51.90 level serves as a critical benchmark for assessing fundamental value.

Organovo (ONVO) - Year-over-year earnings per share growth for the last twelve months from 07/04/2022 to 04/24/2025

Financial and market metric breakdowns for Organovo Holdings, Inc. (ONVO)

- share price and consensus valuation forecast:
Analysis of all company metrics:Organovo Holdings, Inc.
Manufactured product of Organovo Corp

This indicator measures the rate of change in adjusted net earnings per share, allowing investors to promptly identify the deceleration or acceleration of business momentum. By analyzing the quarter-over-quarter EPS dynamics, the market assesses the fundamental stability of Organovo Holdings, Inc. (ONVO), whose growth rates in the 3D bioprinting phase depend not on GDP, but on the availability of venture capital and demand from the pharmaceutical sector.

Competitors of Organovo Holdings, Inc. (ONVO)

ASND (Ascendis Pharma) - Year-over-year net earnings per share growth for the last 12 months|MDGL: Year-over-year earnings per share growth rate for the last twelve months|CORT (Corcept Therapeutics Corp) - Quarterly EPS earnings growth|Quarterly EPS earnings growth Rhythm Pharmaceuticals|Quarterly EPS earnings growth AKRO|Year-over-year earnings per share growth for the last twelve months MTSR (Metsera, Inc.)|Year-over-year earnings per share growth for the last twelve months moonlaketx.com MLTX|Crinetics Corp (CRNX) - Earnings per share growth in annualized terms for the last twelve months|NAMS - Year-over-year earnings per share growth for the last twelve months|SLNO: Year-over-year earnings per share growth for the last twelve months|FOLD: Quarterly EPS earnings growth|ETNB - Year-over-year net earnings per share change for the last twelve months|Year-over-year earnings per share growth for the last twelve months Agios Corp|Structure Corp (GPCR) - Year-over-year net earnings per share change for the last twelve months|Year-over-year earnings per share growth for the last twelve months mimedx.com (MDXG)|Year-over-year net earnings per share growth for the last 12 months rezolutebio.com RZLT|Year-over-year earnings per share growth for the last twelve months Lexicon Pharmaceuticals, Inc. LXRX|MBX Bio - Year-over-year earnings per share growth for the last twelve months|ALT: Year-over-year net earnings per share growth for the last 12 months|AARD - Quarterly EPS earnings growth|SGMT: Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months BioAge Labs, Inc. (BIOA)|Year-over-year earnings per share growth for the last twelve months Biomea Fusion Inc|Year-over-year earnings per share growth for the last 12 months QNCX (Quince Therapeutics)|Year-over-year net earnings per share growth for the last 12 months GUTS (Fractyl Health)|Year-over-year earnings per share growth rate for the last twelve months VTVT|Agape ATP Corporation - Year-over-year net earnings per share growth for the last 12 months|Year-over-year earnings per one share growth for the last 12 months PLUR|Synlogic Inc. - Quarterly EPS earnings growth|LPCN (Lipocine) - Year-over-year earnings per share growth for the last 12 months|MTNB (Matinas BioPharma Holdings Inc.) - Year-over-year net earnings per share growth for the last 12 months|SPRB (Spruce Biosciences, Inc.) - Year-over-year earnings per share growth for the last twelve months|GLTO (galecto.com) - Quarterly EPS earnings growth|Year-over-year net earnings per share growth for the last 12 months carmellrx.com (CTCX)|Year-over-year earnings per share growth for the last twelve months Lumos Pharma (LUMO)|Year-over-year net earnings per share growth for the last 12 months Radius Health RDUS